Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a multi-centre, open label, 2 stage trial in patients with oesophageal cancer

BRIEF SUMMARY

This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer. The design is a phase I, open-label, multicentre, 3-stage, schedule-finding trial using TiTE-CRM (Time-to-Event Continual Reassessment Method).

Our team

  • Sarah Pearson

    OCTO Trial Management Director